Identification of KD5170: A novel mercaptoketone-based histone deacetylase inhibitor

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 23, 2008, Pages 6093-6096

  Payne, Joseph E ^a   Bonnefous, Céline ^a   Hassig, Christian A ^a   Symons, Kent T ^a   Guo, Xin ^a   Nguyen, Phan Manh ^a   Annable, Tami ^a   Wash, Paul L ^a   Hoffman, Timothy Z ^a   Rao, Tadimeti S ^a   Shiau, Andrew K ^a   Malecha, James W ^a   Noble, Stewart A ^a   Hager, Jeffrey H ^a   Smith, Nicholas D ^a  

^a Kalypsys Inc   (United States)

Author keywords

HCT 116; HDAC; Histone deacetylase inhibitor; KD5170; Mercaptoketone; Prodrug; Sulfonamide

Indexed keywords

HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; KD 5170; KETONE DERIVATIVE; THIOL DERIVATIVE; UNCLASSIFIED DRUG;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HCT116 CELLS; HISTONE DEACETYLASES; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICE, NUDE; MOLECULAR STRUCTURE; PRODRUGS; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 55549139738     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.10.029     Document Type: Article

References (18)

1. Wang G.G., Allis C.D., and Chi P. Trends Mol. Med. 13 (2007) 363
2. Xu W.S., Parmigiani R.B., and Marks P.A. Oncogene 26 37 (2007) 5541
3. Gallinari P., Di M.S., Jones P., Pallaoro M., and Steinkuhler C. Cell Res. 17 (2007) 195
4. Glozak M.A., and Seto E. Oncogene 26 (2007) 5420
5. Marks P.A. Oncogene 26 (2007) 1351
6. Marks P.A., and Breslow R. Nat. Biotechnol. 25 (2007) 84
7. Paris M., Porcelloni M., Binaschi M., and Fattori D. J. Med. Chem. 51 6 (2008) 1505
8. Suzuki T., and Miyata N. Curr. Med. Chem. 12 (2005) 2867
9. Bolden J.E., Peart M.J., and Johnstone R.W. Nat. Rev. Drug Discov. 5 (2006) 769
10. Zhou N., Moradei O., Raeppel S., Leit S., Frechette S., Gaudetee F., Paquin I., Bernstein N., Bouchain G., Vaisburg A., Jin Z., Gillespie J., Wang J., Fournel M., Yan P.T., Trachy-Bourget M.C., Kalita A., Lu A., Rahil J., MacLeod R., Li Z., Besterman J.M., and Delormw D. J. Med. Chem. 51 (2008) 4072
11. Konstantinopoulos P.A., Vanoros G.P., and Papavassiliou A.G. Cancer Chemother. Pharmacol. 58 (2006) 711
12. Furumai R., Matsuyama A., Kobashi N., Lee K.H., Nishiyama M., Nakajima H., Tanaka A., Komatsu Y., Nishino N., Yoshida M., and Horinouchi S. Cancer Res. 62 (2002) 4916
13. Wash, P. L.; Hoffman, T. Z.; Wiley, B.M.; Bonnefous, C.; Smith, N. D.; Sertic, M. S.; Lawrence, C. M.; Hassig, C. A.; Symons, K. T.; Guo, X.; Nguyen, P.; Annable, T.; Noble, S. A.; Hager, J. H.; Malecha, J. W. Bioorg. Med. Chem Lett., 2008 (preceding paper).
14. The binding mode of the mercaptoketone maybe mono- or bi-dentate:. Vanommeslaeghe K., Loverix S., Geerlings P., and Tourwe D. Bioorg. Med. Chem. Lett. 13 (2005) 6070
15. Wolter M., Nordmann G., Job G.E., and Buchwald S.L. Org. Lett. 4 (2002) 973
16. Hassig C.A., Symons K.T., Guo X., Nguyen P., Annable T., Wash P.L., Payne J.E., Jenkins D.A., Bonnefous C., Trotter C., Wang Y., Anzola J.V., Milkova E.L., Hoffman T.Z., Dozier S.J., Wiley B.M., Saven A., Malecha J.W., Davis R.L., Shiau A.K., Noble S.A., Rao T.S., Smith N.D., and Hager J.H. Mol. Cancer Ther. 7 (2008) 1054
17. 50) ranged from 0.1 to 7.7 μM with a mean and median of 1.6 and 0.9 μM, respectively.
18. T/C: (Treated final volume - Treated initial volume)/(Control final volume - Control initial volume) × 100. A T/C value of 0 equals tumor stasis.